The specter of generic rivalry has repeatedly loomed around copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the prospects of related drug portfolios. While initial years saw significant profits, the exclusivity end has opened the way for cheaper substitutes, possibly diminis